These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22629725)

  • 41. Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients.
    Mueller M; Castro RE; Thorell A; Marschall HU; Auer N; Herac M; Rodrigues CMP; Trauner M
    Liver Int; 2018 Mar; 38(3):523-531. PubMed ID: 28853202
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment for NASH: the value of histology.
    Elitsur Y; Lawrence Z; Wang R; Durst PR
    Am J Gastroenterol; 2005 Jan; 100(1):250-1. PubMed ID: 15654810
    [No Abstract]   [Full Text] [Related]  

  • 43. [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome].
    Avalueva EB; Tkachenko EI; Skazyvaeva EV; Ivanov SV; Orishak EA; Lapinskiĭ IV
    Eksp Klin Gastroenterol; 2013; (11):26-30. PubMed ID: 24933975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
    Lebensztejn DM
    Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of NASH with ursodeoxycholic acid: pros and cons. More information in children.
    Vajro P; Paolella G; Pierri L; D'Aniello R
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):e93-4. PubMed ID: 23562789
    [No Abstract]   [Full Text] [Related]  

  • 46. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.
    Chamulitrat W; Burhenne J; Rehlen T; Pathil A; Stremmel W
    Hepatology; 2009 Jul; 50(1):143-54. PubMed ID: 19496180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacologic therapy of non-alcoholic steatohepatitis.
    Ratziu V; Zelber-Sagi S
    Clin Liver Dis; 2009 Nov; 13(4):667-88. PubMed ID: 19818312
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis.
    Lin X; Mai M; He T; Huang H; Zhang P; Xia E; Guo H
    Expert Rev Gastroenterol Hepatol; 2022 Jun; 16(6):537-545. PubMed ID: 35617696
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease.
    Gheibi S; Gouvarchin Ghaleh HE; Motlagh BM; Azarbayjani AF; Zarei L
    Biomed Pharmacother; 2019 Jul; 115():108938. PubMed ID: 31071511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ursodeoxycholic acid for nonalcoholic steatohepatitis.
    Wu SD; Li L; Wang JY
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1247-53. PubMed ID: 22864259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.
    Socha P; Horvath A; Vajro P; Dziechciarz P; Dhawan A; Szajewska H
    J Pediatr Gastroenterol Nutr; 2009 May; 48(5):587-96. PubMed ID: 19412008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
    Lee YM; Kaplan MM
    Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. THE EFFECTIVENESS OF COMPLEX THERAPY WITH THE INCLUSION OF THE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
    Khramtsova IO; Derbak MA; Ganich TM; Boldizhar OO; Lazur YV
    Wiad Lek; 2021; 74(10 cz 2):2575-2579. PubMed ID: 34923459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis.
    Orlando R; Azzalini L; Orando S; Lirussi F
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD005160. PubMed ID: 32645206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.
    Itoh S; Kanazuka A; Akimoto T
    Dig Dis Sci; 2003 Nov; 48(11):2182-6. PubMed ID: 14705825
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of ursodeoxycholic acid on prostaglandin metabolism and microsomal membranes in alcoholic fatty liver.
    Lukivskaya OY; Maskevich AA; Buko VU
    Alcohol; 2001 Oct; 25(2):99-105. PubMed ID: 11747979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S; Rustgi VK
    Clin Liver Dis; 2016 May; 20(2):351-64. PubMed ID: 27063274
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.